Aurobindo Pharma creates wholly‑owned step‑down subsidiary PT Auro Pharm Indonesia

What Aurobindo Pharma announced

On 10 July 2026, Aurobindo Pharma Ltd filed a Regulation 30 disclosure with the NSE and BSE, informing the exchanges that its wholly‑owned step‑down subsidiary, PT Aurogen Pharma Indonesia, has incorporated a new wholly‑owned subsidiary named PT Auro Pharm Indonesia in Indonesia. The filing, submitted under SEBI’s Listing Obligations and Disclosure Requirements (LODR) Regulations, provides the basic details of the new entity, its capital structure, and the rationale for its creation.

Details of the newly incorporated subsidiary

PT Auro Pharm Indonesia was incorporated on 1 July 2026 under Indonesian law. The incorporation was approved by the relevant authorities on 9 July 2026, as reflected in Annexure A of the filing. The company is classified in the pharmaceuticals industry and will be set up to undertake manufacturing operations in Indonesia. Because it is a fresh incorporation, there is no historical turnover data available for the last three years.

Share capital, consideration and ownership

The subsidiary’s share capital is IDR 20 billion, divided into 2,000 equity shares of IDR 10 million each. The entire share capital has been subscribed 100 % in cash, meaning Aurobindo’s step‑down subsidiary has provided the full amount as cash consideration. Consequently, Aurobindo Pharma, through PT Aurogen Pharma Indonesia, holds 100 % of the equity in PT Auro Pharm Indonesia, giving it complete control over the new entity.

Related‑party and regulatory aspects

The filing explicitly states that PT Auro Pharm Indonesia is a related‑party transaction because it is a wholly‑owned step‑down subsidiary of Aurobindo Pharma. However, the promoters and promoter group of Aurobindo Pharma have no interest in the transaction, and the acquisition is being carried out at arm’s length. No governmental or regulatory approvals are required for the incorporation, and there is no stipulated time‑frame for completion because the subsidiary is already incorporated and fully funded.

"The object of incorporation of this wholly owned step‑down subsidiary is to undertake manufacturing operations in Indonesia." – Annexure A, Regulation 30 filing.

Key facts at a glance

Why this matters for investors

The creation of PT Auro Pharm Indonesia expands Aurobindo Pharma’s manufacturing footprint into Indonesia, a market with a growing demand for generic medicines. Because the subsidiary is wholly owned, any future earnings, assets, or liabilities will ultimately be consolidated into Aurobindo’s financial statements, subject to applicable accounting standards. The cash‑only subscription means there is no immediate dilution of existing shareholders’ equity. However, the investment does tie up cash resources, and the performance of the Indonesian manufacturing unit will depend on market conditions, regulatory environment, and operational execution in the coming years.

Conclusion

Aurobindo Pharma has formally announced the incorporation of PT Auro Pharm Indonesia, a wholly‑owned step‑down subsidiary created to carry out pharmaceutical manufacturing in Indonesia. The subsidiary is fully funded with a cash‑only share subscription of IDR 20 billion and requires no further regulatory clearances. While the move does not affect shareholding patterns, it signals the company’s intent to broaden its production base internationally. Investors should monitor future disclosures for operational updates and any impact on the group’s consolidated financials.